
These birds carry a toxin deadlier than cyanide
New Guinea is home to some of the world's most toxic birds. Why they contain poison, and how they withstand the it is still a source of scientific mystery. The variable pitohui, a poisonous bird, captured in mist net on the outskirts of Wanang Village in Papua New Guinea in 2018. Photographs By Knud Jønsson
In the summer of 1989, Jack Dumbacher was a fresh-faced ornithologist-in-training on his maiden expedition to the lush rainforests of Papua New Guinea. One sticky afternoon, he noticed an unusual bird with gaudy black-and-orange feathers entangled in his mist nets. But as Dumbacher tried to set it free, the hooded pitohui scratched him.
'They're jay-sized birds with needle-sharp claws and bills,' says Dumbacher, who instinctively put the cut to his lips. 'My mouth started to tingle and burn, and then went numb, lasting until the night.'
When Dumbacher consulted his local guides, they nodded knowingly, telling him how villagers would avoid the 'rubbish birds,' eating them only if they were 'skinned and specially prepared.' Curiosity piqued, the then-graduate student at the University of Chicago spent the next year collecting pitohui samples and searching for a chemist back home who could pinpoint the source of the peculiar sensations.
In 1992, Dumbacher and his collaborators announced their astonishing findings: hooded pitohuis carry batrachotoxin. The toxin is deadlier than cyanide and is among the most lethal substances in the animal kingdom. It's the same substance found in certain poison dart frogs halfway round the world.
Since then, at least a dozen other avian species, out of more than 10,500 known to science, have been identified as toxic. Some members of this select group—such as the European quail, North American ruffed grouse, and European hoopoes —are found outside of New Guinea and contain different toxins. The majority, however, are batrachotoxin-carrying and endemic to the world's second largest island, including at least five other pitohui species and the blue-capped ifrit.
But 35 years on from Dumbacher's serendipitous discovery, much remains a mystery about New Guinea's poisonous birds. 'There's a ton that we don't know—from the ecology of the birds to how they use batrachotoxin for defense and where they get it from,' says Dumbacher, now California Academy of Sciences' curator of birds and mammals.
He last visited the island in 2011, and another team of scientists—led by ecologist Knud Jønsson from the Swedish Museum of Natural History and evolutionary and community biologist Kasun Bodawatta at the University of Copenhagen—are continuing Dumbacher's research. Already, they've made inroads, identifying two new toxic bird species in 2023, the first discovery in nearly two decades. They plan to visit Papua New Guinea annually until 2028.
They hope to answer a key question: where does the toxin—believed to protect the birds from predators and parasites—come from?
One theory for the origin of this poison is the birds' diet.
'It's been put forth that they eat these Choresine beetles and that's how they get their toxin,' says Jønsson. 'But in reality, we don't know.'
Dumbacher—who, in 2004, was the first to describe how batrachotoxin is present in both birds and beetles—doesn't believe the toxin originates in the tiny rice-sized insects.
'Most of the information suggests that beetles can't produce such steroidal alkaloids,' he says. 'So it's very possible that the beetles are getting it from some other source like soil mites or even a plant.'
To track batrachotoxin's origin, the researchers plan to collect poisonous birds and compare their stomach contents to insects caught in nearby traps. 'The idea is to try and home in on potential prey items that have the toxin,' explains Jønsson. 'It's very much looking for a needle in a haystack, but that's the very first step that we can take.'
They've also teamed up with Christine Beemelmanns, a chemist at Germany's Saarland University to pinpoint batrachotoxin and molecularly similar toxins in the samples already collected.
Tests have shown that poisonous birds contain a mixture of toxic derivatives—Beemelmanns' lab has identified six so far—which can vary in concentration between individuals and species. The hooded pitohui is one of several poisonous birds that have been documented in Papua New Guinea. While poisonous birds have been documented in North America and Europe, the majority known to science are found in the this South Pacific region. Photographs By Knud Jønsson How do birds remain immune?
Another enduring mystery is how the birds protect themselves from the deadly toxin they carry.
Batrachotoxin binds to sodium ion channels in nerve, muscle, and heart cells, resulting in numbness, convulsions, paralysis, and even death. 'It sits on these channels and keeps them open, so the nerves just go on twitching,' says Jønsson.
Poisonous birds contain far less toxin than the golden poison frog, which carries enough batrachotoxin to kill 10 grown men. The hooded pitohui—the most toxic avian species—isn't lethal when handled or consumed.
The longstanding theory that explains how the birds 'aren't killing themselves' is that they, like poison dart frogs, contain mutations in their sodium channels, which prevents the toxin from binding, says Daniel Minor, a biophysicist at the University of California, San Francisco, who's not involved with Jønsson and Bodawatta's upcoming research expeditions.
The same trait is found in the fugu pufferfish, blue-ringed octopus, and other poisonous animals that remain impervious to the toxins they carry.
Indeed, when Jønsson and his collaborators compared the genomes of six toxic bird species with their non-toxic cousins within the same families, they discovered that poisonous birds contained multiple mutations in a gene encoding a specific sodium channel.
However, when Minor's team conducted electrophysiological tests on genes cloned from the southern variable pitohui in a separate set of experiments, they 'were distraught' to discover that the sodium channels remained sensitive to batrachotoxin—despite their mutations.
Minor now believes that the birds' resistance lies in an as-yet-unidentified protein which acts as a 'toxin sponge,' binding to batrachotoxin and sequestering it. He and his colleagues' work on saxitoxin, another protein that binds to sodium channels, provided this insight.
'Our lab showed that saxiphilin, a protein found naturally in poison dart frogs, can scoop in and bind to saxitoxin with high affinity,' he explains. 'So maybe it's the same for batrachotoxin.'
Jønsson and Bodawatta think the two mechanisms might be complementary. 'Birds, anyway, need to transport batrachotoxin from the gut to the skin,' says Bodawatta. 'So they must have a transporter protein that facilitates this.' Are there more?
Scientists' are keen to know whether more toxic birds exist.
Jønsson thinks it's highly likely. "New Guinea's poisonous birds belong to the Corvides super-family of birds, which comprise roughly 700 species worldwide,' he says. New Guinea is home to 140 of them, and his team has so far studied just a fifth of them.
Starting this November, his team will collect 'as many Corvides samples as possible' from different parts of the island and screen them for batrachotoxin. They also plan to sequence as least one individual per species to identify sodium channel mutations.
A more comprehensive genomic dataset will also allow scientists to identify possible toxin sponge proteins, adds Bodawatta.
More broadly, the researchers want to study 'the super cool and crazy convergent evolution' that's allowed for this special toxin resistance in both frogs and birds, as well as unrelated avian species within New Guinea and elsewhere in the world, Bodawatta says.
'Understanding convergent adaptations by natural selection is a central goal in evolutionary biology,' adds Jønsson.
The more scientists learn about what exists, the more questions they'll be able to ask about why they do.
'Maybe in two to three years, we'll have some new insights to share,' says Bodawatta. 'This is just the beginning.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Navigate EU Clinical Trial Regulations with Confidence: Virtual Seminar on EU Clinical Trial Regulation - EU Filings & Registrations
This comprehensive course on EU Clinical Studies covers the EU Clinical Trial Regulation, EU-GCP updates, and new Pharmacovigilance Directive insights. Attendees will learn about EU regulatory frameworks, licensing methods, and effective submission strategies. The seminar includes Q&A, handouts, and certificates. Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Virtual Seminar on The EU Clinical Trial Regulation - EU Filings & Registration (August 20, 2025)" has been added to offering. This course covers the requirements for conducting Clinical Studies across the EU via the requirements of the EU Clinical Trial Regulation (for Drugs & Biologics). The course also covers recent updates on EU-GCP associated with the new regulatory framework and highlights the new EU Pharmacovigilance Directive, as it relates to studies and helpful tips for working with European regulators. The seminar covers the impending changes coming with the EU Parliament's passage of the EU Clinical Trial Regulation, which will affect all trials conducted across the EU [new and ongoing]. This course also covers the various licensing methods (for Drugs, Biologics & Combination Products) by which applicants can file for product licenses (Marketing Authorizations) in one or multiple Member States [and EEA], as well as fully across all Member States of the European Union. This course specifically outlines and discusses the structure of the regulatory agencies at the EU level and across the specific Member States. Course content will explain which procedures are available for which products and then will follow the license processing steps for each pathway. Learning Objectives Attendees will leave the Course clearly understanding the requirements under the current Regulations. In addition, this course has been updated to provide participants with competitive insight into: How the EU and individual countries within Europe Interact Which registration procedure to use How regulations affect product development strategies Understanding the concerns/issues of European Regulatory Personnel How to negotiate with the regulators Information necessary for effective submissions Strategies for streamlining the registration application process for faster approval The advantages and disadvantages of various registration procedures How to efficiently initiate trials first patient, first visit How to link the strategy of Country Selection to an ultimate EU registration pathway How to stay compliant What can make the difference in your data passing Regulatory scrutiny Related area-GCP and PV-reporting updates Impending Changes of the EU Clinical Trial Regulation and timing for Implementation This live training Seminar includes the following for each registered attendee: A copy of the presentation slides by download A certificate of participation for attendee training records Q/A Session Free Handouts on EU Clinical Trial Regulation Who Should Attend: Business Management Project Team Members Legal Team Members Clinical Operations Staff Quality Assurance, Monitors, CRAs Regulatory Affairs Investigators & Site Study Staff CROs, Consultants, Insurers Course Agenda: Session 1: EU's New Regulation 535/2014 on Clinical Trials, 2022 (77 slides) Introduction - Foundation of Science-based Clinical Trials Clinical Trial Basics EU Regulation 536/2014, recently implemented Trial subjects' concerns / rights Session 2: ICH Q7, API CGMPs and QMS (81 slides) ICH Q7 API CGMP Additional CGMP considerations Required Records Methods Validation Session 3: Risk Management in EU New Drug Development (53 slides) ICH Q9 Risk Management File - Narrative Hazards List, FTA, D-, P-, U-FME[C]A's Review / Report; Use Session 4: Investigational Medicinal Products (IMPs) (22 slides) EU Medicinal Products Requirements IMPs Session 5: EU Clinical Trials Application Process (36 slides) Application Process AMS, CMS Required documents. Review Q & A For more information about this webinar visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio


Atlantic
3 hours ago
- Atlantic
Get Ready to Hear a Lot More About Your Mitochondria
Robert F. Kennedy Jr.'s warning about mitochondria slipped in between the anti-vaccine junk science and the excoriation of pharmaceutical drugs as 'the No. 3 killer in our country.' He was speaking in 2023 to Joe Rogan, elaborating on the dangers of Wi-Fi—which no high-quality scientific evidence has shown to harm anyone's health—and arguing that it causes disease by somehow opening the blood-brain barrier, and by degrading victims' mitochondria. The mention of mitochondria—the tiny structures that generate energy within our cells—was brief. Two years later, mitochondrial health is poised to become a pillar of the MAHA movement, already showing up in marketing for supplements and on podcasts across the 'manosphere.' Casey Means, President Donald Trump's newest nominee for surgeon general, has singled out the organelle as the main casualty of the modern American health crisis. According to Means (who has an M.D. but no active medical license), most of America's chronic ailments can be traced to mitochondrial dysfunction. Should she be confirmed to the post of surgeon general, the American public can expect to hear a lot more about mitochondria. Among scientists, interest and investment in mitochondria have risen notably in the past five years, Kay Macleod, a University of Chicago researcher who studies mitochondria's role in cancer, told me. Mitochondria, after all, perform a variety of crucial functions in the human body. Beyond powering cells, they can affect gene expression, help certain enzymes function, and modulate cell death, Macleod said. When mitochondria are defective, people do indeed suffer. Vamsi Mootha, a mitochondrial biologist based at Massachusetts General Hospital and the Broad Institute, told me that rare genetic defects (appearing in about one in 4,300 people) can cause the organelles to malfunction, leading to muscle weakness, heart abnormalities, cognitive disability, and liver and kidney problems. Evidence also suggests that defects in mitochondria directly contribute to symptoms of Parkinson's disease, and could be both a cause and an effect of type 2 diabetes. Other conditions' links to mitochondria are blurrier. Researchers see aberrant mitochondria in postmortem biopsies of patients with illnesses such as Alzheimer's, cancer, and fatty-liver disease, Mootha said; whether those damaged mitochondria cause or result from such conditions is not yet clear. But according to Good Energy, the book Means published last year with a top MAHA adviser—her brother, Calley—mitochondrial dysfunction is a veritable plague upon the United States, responsible for both serious illness and everyday malaise. In their view, modern Western diets and lifestyles wreck countless Americans' metabolic health: Every time you drink unfiltered water or a soda, or feel the stress of mounting phone notifications, you hurt your mitochondria, they say, triggering an immune response that in turn triggers inflammation. (Damaged mitochondria really can cause inflammation, Macleod said.) This chain of events, the Meanses claim, can be blamed for virtually every common chronic health condition: migraines, depression, infertility, heart disease, obesity, cancer, and more. (Casey Means did not respond to requests for comment; reached by email, Calley did not respond to my questions about mitochondria, but noted, 'There is significant scientific evidence that healthy food, exercise and sleep have a significant impact on reversing chronic disease.') Good Energy follows a typical wellness playbook: using a mixture of valid and dubious research to pin a slew of common health problems on one overlooked element of health—and advertising a cure. Among the culprits for our mitochondrial ravaging, according to the Meanses, are poor sleep, medications, ultraprocessed foods, seed oils, too many calories, and too few vitamins, as well as chronically staying in comfortable ambient temperatures. The Means siblings therefore recommend eschewing refined sugar in favor of leafy greens, avoiding nicotine and alcohol, frequenting saunas and cold plunges, getting seven to eight hours of uninterrupted sleep a night, and cleansing your life of environmental toxins. Some studies indeed suggest that mitochondrial function is linked with sleep and temperature, but they've all been conducted on cell cultures, organoids, or mice. According to Macleod, evidence suggests that diet, too, is likely important. But only one lifestyle intervention— exercise —has been definitively shown to improve mitochondrial health in humans. The Meanses are riding a wave of interest in mitochondrial health in the wellness world. Earlier this year, the longevity influencer Bryan Johnson and the ivermectin enthusiast Mel Gibson both endorsed the dye methylene blue for its power to improve mitochondrial respiration; Kennedy was filmed slipping something that looks a lot like methylene blue into his drink. (Kennedy did not respond to a request for comment; the FDA has approved methylene blue, but only as a treatment for the blood disease methemoglobinemia.) AG1, formerly known as Athletic Greens, formulates its drinkable vitamins for mitochondrial health. Even one laser-light skin treatment promises to 'recharge failing mitochondria.' The enzyme CoQ10 is popular right now as a supplement for mitochondrial function, as is NAD, a molecule involved in mitochondria's production of energy. NAD IV drips are especially beloved by celebrities such as Gwyneth Paltrow, Kendall Jenner, and the Biebers. These supplements are generally thought to be safe, and some preliminary research shows that NAD supplementation could help patients with Parkinson's or other neurodegenerative diseases, and that CoQ10 could benefit people with mitochondrial disorders. Patients whose symptoms are clearly caused or made worse by deficiencies in a specific vitamin, such as thiamine, can benefit from supplementing those vitamins, Mootha said. But little research explores how these supplements might affect healthy adults. In Good Energy, as well as on her website and in podcast appearances, Casey Means promotes a number of supplements for mitochondrial health. She also recommends that people wear continuous glucose monitors—available from her company, Levels Health, for $184 a month—to help prevent overwhelming their mitochondria with too much glucose. (According to Macleod, glucose levels are only 'a very indirect measure' of mitochondrial activity.) As with so many problems that wellness influencers harp on, the supposed solution to this one involves buying products from those exact same people. At best, all of this attention to mitochondria could lead Americans to healthier habits. Much of the advice in Good Energy echoes health recommendations we've all heard for decades; getting regular exercise and plenty of fiber is good guidance, regardless of anyone's reasons for doing so. Switching out unhealthy habits for healthy ones will likely even improve your mitochondrial health, Jaya Ganesh, a mitochondrial-disease expert at Icahn School of Medicine at Mount Sinai, told me. After all, 'if you consistently beat your body up with unhealthy habits, everything is going to fall sick,' Ganesh said. But the mitochondrial approach to wellness carries risks, too. For patients with genetically caused mitochondrial disease, lifestyle changes might marginally improve some symptoms, Ganesh said, but attempting to cure such conditions with supplements and a healthy diet alone could be dangerous. Means also calls out medications—including antibiotics, chemotherapy, antiretrovirals, statins, and high-blood-pressure drugs—for interfering with mitochondria. Macleod told me that statins really do affect mitochondria, as do some antibiotics. (The latter makes sense: Mitochondria are thought to have evolved from bacteria more than a billion years ago.) That's no reason, though, to avoid any of these medications if a doctor has determined that you need them. And yet, a whole chapter of Good Energy is dedicated to the idea that readers should mistrust the motives of their doctors, who the authors say profit by keeping Americans sick. The book is less critical of the ways the wellness industry preys on people's fears. Zooming in on mitochondria might offer a reassuringly specific and seemingly scientific explanation of the many real ills of the U.S. population, but ultimately, Means and MAHA are only helping obscure the big picture.


CNBC
3 hours ago
- CNBC
Field: Vaccine fatigue has caused flu vaccination rates to fall slightly
Emily Field, Barclays head of European pharma research, discusses RFK Jr.'s call to overhaul the CDC vaccine panel, vaccine skepticism, and the impact on stocks like Merck amid new RSV vaccine approvals.